FindTrial
Sign In

Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)

Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220018
Enrollment
Unknown
Registered
2005-09-02
Start date
2005-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : MRA (tocilizumab) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for In

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR) (2) Between 20 and 75 years old

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: Frequency of ACR improvement Safety: Frequency and severity of adverse events and adverse drug reactions—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026